MBI files IND application for Oralex

Article

Ultrasound contrast agentdeveloper Molecular Biosystems this month took another step towardcommercializing a new ultrasound agent. The San Diego-based firmhas filed an investigational new drug (IND) application with theFood and Drug Administration for

Ultrasound contrast agentdeveloper Molecular Biosystems this month took another step towardcommercializing a new ultrasound agent. The San Diego-based firmhas filed an investigational new drug (IND) application with theFood and Drug Administration for Oralex, an oral ultrasound agentfor abdominal imaging.

Oralex is designed to fill the stomach and upper gastrointestinaltract, displacing air and improving visualization of organs suchas the pancreas and gallbladder. MBI estimates that about fourmillion abdominal ultrasound scans are performed each year inthe U.S.

Pending FDA approval of the IND, MBI will sponsor phase-oneclinical trials at two university sites. The primary goals ofthe trials will be to evaluate the safety, preliminary efficacyand dose-ranging effects of Oralex.

MBI has licensed European rights to Oralex to Italian contrastsupplier Bracco of Milan (SCAN 6/30/93). MBI does not have a licensingpartner for the agent outside Europe.

In addition to proceeding with clinical development of Oralex,MBI has cleared up legal interference with competitor ImaRx Pharmaceuticalconcerning the agent. ImaRx, of Tucson, AZ, filed suit againstMBI last year, alleging that MBI misappropriated ImaRx trade secretsto develop Oralex (SCAN 7/14/93). ImaRx is developing SonoRx,an oral gastrointestinal ultrasound agent licensed to Squibb Diagnostics.

In a lawsuit filed in the U.S. District Court of Arizona, ImaRxalleged that MBI violated a non-disclosure agreement by usingproprietary information about ImaRx technology to develop Oralex.

MBI and ImaRx settled the lawsuit and a related patent infringementclaim in May, according to Sherry L. Mesman, CFO and vice presidentof finance for MBI. MBI did not disclose the terms of the settlement.

In other MBI news, the company said that researchers at OschnerMedical Institution in New Orleans reported successful resultsin canine testing with FS069, a new second-generation contrastagent for transpulmonary myocardial perfusion echocardiography.The results were reported at the American Society of Echocardiographymeeting in San Francisco last month.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.